Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expression-linked promoter selection (ELiPS) engineers short, strong ubiquitous promoters for gene therapy applications.

bioRxiv : the preprint server for biology·2026
Same author

Optogenetic WNT signaling drives germ layer self-organization in a human gastruloid model.

bioRxiv : the preprint server for biology·2026
Same author

Directed evolution of novel AAV capsids for enhanced delivery to mouse and human Schwann cells.

Molecular therapy. Nucleic acids·2026
Same author

Adeno-associated virus serotype 9 structural heterogeneity and stability characterized by charge detection mass spectrometry.

Molecular therapy. Methods & clinical development·2025
Same author

Ocular Delivery of Viral Vectors for Retinal and Choroidal Vascular Diseases: A Review.

American journal of ophthalmology·2025
Same author

Nickase fidelity drives EvolvR-mediated diversification in mammalian cells.

Nature communications·2025
Same journal

Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Neonatal systemic gene therapy restores cardiorespiratory function in a rat model of Pompe disease.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Endothelial injury with capillary leak: A final common pathway in acute AAV toxicity?

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Long-term functional synaptic integration of genome-edited retinal organoids in a primate model of macular degeneration.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Nox1/4 inhibitor Setanaxib treatment ameliorates cardiac function in mouse models of Duchenne Muscular Dystrophy.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

HSP90α-USP7-DNMT1 Axis Drives Hepatocellular Carcinoma Recurrence After Microwave Ablation by Disrupting ACSS3-Mediated Propionate Metabolism.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
See all related articles

Related Experiment Video

Updated: May 16, 2025

Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus AAV Capsid Variants
09:20

Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus AAV Capsid Variants

Published on: October 18, 2022

4.4K

Advances in AAV capsid engineering: Integrating rational design, directed evolution and machine learning.

Alan M Nisanov1, Julio A Rivera de Jesús2, David V Schaffer3

  • 1Department of Chemistry, University of California, Berkeley, Berkeley CA 94720, USA.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|April 3, 2025
PubMed
Summary
This summary is machine-generated.

Engineered adeno-associated virus (AAV) capsids overcome limitations of natural serotypes for gene therapy. Novel capsid engineering strategies improve transduction efficiency, reduce immunogenicity, and enhance tissue targeting for clinical applications.

Keywords:
AAVNGSdirected evolutiongene therapyhigh-throughput screeningmachine learningnext generation sequencingrational design

More Related Videos

Engineering and Evolution of Synthetic Adeno-Associated Virus AAV Gene Therapy Vectors via DNA Family Shuffling
21:55

Engineering and Evolution of Synthetic Adeno-Associated Virus AAV Gene Therapy Vectors via DNA Family Shuffling

Published on: April 2, 2012

28.3K
Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors
09:21

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors

Published on: January 29, 2019

35.8K

Related Experiment Videos

Last Updated: May 16, 2025

Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus AAV Capsid Variants
09:20

Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus AAV Capsid Variants

Published on: October 18, 2022

4.4K
Engineering and Evolution of Synthetic Adeno-Associated Virus AAV Gene Therapy Vectors via DNA Family Shuffling
21:55

Engineering and Evolution of Synthetic Adeno-Associated Virus AAV Gene Therapy Vectors via DNA Family Shuffling

Published on: April 2, 2012

28.3K
Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors
09:21

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors

Published on: January 29, 2019

35.8K

Area of Science:

  • Biotechnology and Gene Therapy
  • Viral Vector Engineering

Background:

  • Adeno-associated virus (AAV) is a promising vector for human gene therapy, offering a good safety profile and broad tissue transduction.
  • Natural AAV serotypes possess limitations such as low transduction efficiency, pre-existing immunity, and poor tissue specificity, restricting their therapeutic use.

Purpose of the Study:

  • To engineer novel adeno-associated virus (AAV) capsids to overcome the limitations of natural serotypes.
  • To improve AAV vector properties for enhanced gene therapy applications.

Main Methods:

  • Rational design leveraging structural insights to optimize capsid properties.
  • Directed evolution for unbiased selection of superior AAV variants.
  • Machine learning and computational analysis of high-throughput screening data to develop predictive algorithms.

Main Results:

  • Development of novel AAV capsids with significantly improved transduction efficiency.
  • Engineered capsids demonstrate reduced immunogenicity compared to natural serotypes.
  • Enhanced tissue targeting capabilities achieved through capsid engineering.

Conclusions:

  • Multi-disciplinary approaches integrating rational design, directed evolution, and machine learning are effective in engineering improved AAV capsids.
  • These advancements are crucial for overcoming current challenges and accelerating the clinical translation of AAV-based gene therapies.